Miniatura

Fitxers

HEP-22-0918.R2_Proof_hi.pdf (1.1 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-04-01

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/203640

Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predni(so)lone administration

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1097/hep.0000000000000018

Resum

In patients with non-severe acute or chronic autoimmune hepatitis (AIH) without cirrhosis, clinical practice guidelines recommend indistinct use of prednisone or budesonide. However, budesonide is infrequently used in clinical practice. We aimed to describe its use and compare its efficacy and safety with prednisone as first-line options.This was a retrospective, multicenter study of 105 naive AIH patients treated with budesonide as the first-line drug. The control group included 276 patients treated with prednisone. Efficacy was assessed using logistic regression and validated using inverse probability of treatment weighting propensity score. The median time to biochemical response (BR) was 3.1 months in patients treated with budesonide and 4.9 months in those with prednisone. The BR rate was significantly higher in patients treated with prednisone (87% vs. 49% of patients with budesonide, p < 0.001). The probability of achieving BR, assessed using the inverse probability of treatment weighting propensity score, was significantly lower in the budesonide group (OR = 0.20; 95% CI: 0.11-0.38) at any time during follow-up, and at 6 (OR = 0.51; 95% CI: 0.29-0.89) and 12 months after starting treatment (0.41; 95% CI: 0.23-0.73). In patients with transaminases <2 × upper limit of normal, BR was similar in both treatment groups. Prednisone treatment was significantly associated with a higher risk of adverse events (24.2% vs. 15.9%, p = 0.047).In the real-life setting, the use of budesonide as first-line treatment is low, and it is generally prescribed to patients with perceived less disease activity. Budesonide was inferior to prednisone as a first-line drug but was associated with fewer side effects.Copyright © 2023 American Association for the Study of Liver Diseases.

Matèries

Hepatitis, Malalties autoimmunitàries, Corticosteroides

Matèries (anglès)

Hepatitis, Autoimmune diseases, Adrenocortical hormones

Citació

Col·leccions

Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

DÍAZ GONZÁLEZ, Álvaro, HERNÁNDEZ GUERRA, Manuel, PÉREZ MEDRANO, Indhira, SAPENA, Víctor, RIVEIRO-BARCIELA, Mar, BARREIRA DÍAZ, Ana, GÓMEZ, Elena, MORILLAS, Rosa m., BARRIO, María del, ESCUDÉ, Laia, MATEOS, Beatriz, HORTA, Diana, GÓMEZ, Judith, CONDE, Isabel, FERRE ARACIL, Carlos, EL HAJRA, Ismael, ARENCIBÍA, Ana, ZAMORA, Javier, FERNÁNDEZ, Ainhoa, SALCEDO, Magdalena, MOLINA, Esther, SORIA, Anna, ESTÉVEZ, Pamela, LÓPEZ, Carmen, ÁLVAREZ NAVASCUÉS, Carmen, GARCÍA RETORTILLO, Montserrat, CRESPO, Javier, LONDOÑO, María carlota, ColHai Registry. Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predni(so)lone administration. _Hepatology_. 2023. Vol. 77, núm. 4, pàgs. 1095-1105. [consulta: 23 de gener de 2026]. ISSN: 1527-3350. [Disponible a: https://hdl.handle.net/2445/203640]

Exportar metadades

JSON - METS

Compartir registre